MPO

Across TCGA pan-cancer cohorts, MPO Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated MPO data layer compared with 29 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher MPO Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MPO expression acts as an unfavorable survival marker.

KIRC, LUAD, and SCLC are the cancer types where MPO Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	OS	Median	II,III,IV	0.054	0.806	<.001	48	view →
LUAD	OS	Median	III,IV	0.057	0.680	<.001	12	view →
SCLC	DFS	Median	II,III,IV	0.137	0.562	.013	9	view →
READ	DFS	Median	II,III,IV	0.182	0.792	.016	6	view →
PRAD	DFS	Median	All	0.465	0.888	<.001	6	view →
LIHC	DFS	Median	All	0.202	0.559	.006	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	DFS	Median	III,IV	0.092	0.273	.020	4	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

MPO–KIRC (OS)

Open the KIRC breakdown →